How is China Shaping the Face of the Pharma Industry?

We have taken some of the key highlights from the Scrip webinar “How Is China Changing The Face Of The Pharmaceutical Industry?”, to create an exclusive infographic. Created by Editor in Chief, Eleanor Malone, this infographic distils the latest trends, data, and strategic insights driving innovation, partnerships, and regulatory change in China’s pharmaceutical sector.

Discover how China is reshaping the global biopharma landscape.

Three Key Things You’ll Learn:

R&D Explosion: China's Pipeline Dominance
Explore how China’s biopharma sector now accounts for nearly a third of global R&D firms and 25% of the worldwide drug pipeline.
Innovation Highlights: China’s Breakthroughs
See which Chinese companies are now ranked among the world’s top R&D engines
Dealmaking Boom: Top Five Deals With Chinese Biopharma
With billions in deal value, discover the top five recent transactions between Chinese and Western pharma leaders.

Complete the form to download.

First Name *

Last Name *

Company *

Job Title *

Business Email Address *

Country *

Business Phone

How Can We Help

fieldlabel

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

About the author

Eleanor Malone

Editor in Chief, Commercial Insights

Eleanor directs editorial content produced by the Commercial Pharma Insights team (Scrip, Generics Bulletin and In Vivo) in the US and Europe, liaising closely with counterparts in policy and regulatory coverage and in Asia. She oversees and contributes to daily analytical content based on biopharma industry developments and trends, interviewing key experts and industry leaders.

Eleanor joined Citeline predecessor Informa in 2000 as companies reporter on Scrip, and has held a number of editorial roles on Citeline's pharma and medtech publications. She has interviewed countless industry leaders and specialists, explored business developments and strategy, pipeline trends, policy and regulatory stories, delved into M&A, licensing, partnerships, financing, financial reports, clinical trial updates, market trends and more. She regularly appears on conference panels and in the media to discuss matters relating to the biopharma industry.

She has an MA in modern languages from the University of Edinburgh and previously worked as a translator of European business news for the Financial Times.